Loading
A phase 2 trial of pembrolizumab and olaparib in triple-negative breast cancer, run by Memorial Sloan Kettering Cancer Center, now recruiting.
A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer is a phase 2, interventional study registered as NCT04683679 by Memorial Sloan Kettering Cancer Center, with a registry enrolment figure of 34 participants, started 2021-04-21 and due to reach its primary completion in 2027-01. Interventions recorded: Pembrolizumab; Olaparib; Radiation. Conditions listed: Triple Negative Breast Cancer; TNBC - Triple-Negative Breast Cancer; Breast Cancer; Metastatic Breast Cancer. Triple-negative eligibility wording from the registry: "* Female participants who are at least 18 years of age on the day of signing informed consent with histologically confirmed diagnosis of triple negative breast cancer or ER+/Her2 will be enrolled in this study". Sites: United States. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares PARP inhibitors, Olaparib, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares PARP inhibitors, Olaparib, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Pembrolizumab and the tag tnbc-deep-dive.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Pembrolizumab, Immune checkpoint inhibitors and the tag tnbc-deep-dive.
Shares PARP inhibitors, Olaparib, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares PARP inhibitors, Olaparib, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Pembrolizumab, Immune checkpoint inhibitors and the tag tnbc-deep-dive.
Shares PARP inhibitors, Olaparib, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Pembrolizumab and the tag tnbc-deep-dive.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Pembrolizumab, Immune checkpoint inhibitors and the tag tnbc-deep-dive.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/